Mental Health Consequences of COVID19 Infection in the French RMD Cohort

Mental Health Consequences of COVID19 Infection in the French Rheumatic Musculoskeletal Diseases (RMD) Cohort

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04510467

Acronym

MentCovid19RMD

Enrollment

296

Registered

2020-08-12

Start date

2021-01-20

Completion date

2022-05-19

Last updated

2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Auto Inflammatory Diseases, Covid19, Inflammatory Rheumatism, Systemic Autoimmune Disease

Brief summary

this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patient case: * Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease * With confirmed COVID-19 infection (at least one month prior to study inclusion) * Study information given to the patient * Patient affiliated to social security Patient control: * Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune disease. * Not having had a confirmed COVID-19 infection * Study information given to the patient * Patient affiliated to social security

Exclusion criteria

* Opposition to participation in the study by the patient and/or his legal representative * Adult patient not able to understand the implications and rules of the study * Protected adults under guardianship or curatorship

Design outcomes

Primary

Measure	Time frame
Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID	at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection

Secondary

Measure	Time frame
Severity of PTSD depending on whether or not autoimmune patients have experienced COVID	at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection

Countries

France

Outcome results